Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

NCT05025605 is registered in ClinicalTrials.gov with BioXcel Therapeutics Inc as lead sponsor.

NCT NCT05025605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05025605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Lead sponsor
BioXcel Therapeutics Inc
Phase
Phase 1
Overall status
Recruiting
Start date
August 27, 2021
Completion date
December 31, 2027
Enrollment
140 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder i, bipolar disorder ii, schizo-affective disorder, schizophrenia, schizophreniform; schizophrenic